JP2011510667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510667A5 JP2011510667A5 JP2010545343A JP2010545343A JP2011510667A5 JP 2011510667 A5 JP2011510667 A5 JP 2011510667A5 JP 2010545343 A JP2010545343 A JP 2010545343A JP 2010545343 A JP2010545343 A JP 2010545343A JP 2011510667 A5 JP2011510667 A5 JP 2011510667A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- polypeptide
- composition
- cartilage degeneration
- progression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 36
- 229920001184 polypeptide Polymers 0.000 claims description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 210000000845 cartilage Anatomy 0.000 claims description 19
- 230000007850 degeneration Effects 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 11
- 201000008482 osteoarthritis Diseases 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 229940039227 diagnostic agent Drugs 0.000 claims description 4
- 239000000032 diagnostic agent Substances 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 239000008366 buffered solution Substances 0.000 claims description 2
- 239000013599 cloning vector Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 102000003675 cytokine receptors Human genes 0.000 claims description 2
- 108010057085 cytokine receptors Proteins 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2631708P | 2008-02-05 | 2008-02-05 | |
| US8887608P | 2008-08-14 | 2008-08-14 | |
| PCT/CH2009/000045 WO2009097704A1 (en) | 2008-02-05 | 2009-02-05 | Antigen-binding polypeptides against cartilage degeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011510667A JP2011510667A (ja) | 2011-04-07 |
| JP2011510667A5 true JP2011510667A5 (enExample) | 2013-01-24 |
Family
ID=40568129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010545343A Pending JP2011510667A (ja) | 2008-02-05 | 2009-02-05 | 軟骨変性に対する抗原結合性ポリペプチド |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110002927A1 (enExample) |
| EP (1) | EP2240515A1 (enExample) |
| JP (1) | JP2011510667A (enExample) |
| CN (1) | CN101939335B (enExample) |
| AU (1) | AU2009212079B2 (enExample) |
| BR (1) | BRPI0907485A2 (enExample) |
| CA (1) | CA2712965A1 (enExample) |
| IL (1) | IL206720A0 (enExample) |
| RU (1) | RU2010136988A (enExample) |
| WO (1) | WO2009097704A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013540757A (ja) | 2010-09-24 | 2013-11-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル |
| CN104231086B (zh) * | 2013-08-27 | 2019-12-13 | 北京韩美药品有限公司 | 双功能融合蛋白及其制备方法和用途 |
| SG11201604227XA (en) * | 2013-12-13 | 2016-07-28 | Mercury Asset Man Co Ltd | Articular cartilage imaging composition |
| EP3978022A1 (en) * | 2016-05-06 | 2022-04-06 | The Brigham and Women's Hospital, Inc. | Binary self assembled gels for controlled delivery of encapsulated agents to cartilage |
| US11839605B2 (en) | 2018-10-11 | 2023-12-12 | Alivio Therapeutics, Inc. | Non-injectable hydrogel formulations for smart release |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| ES2424042T3 (es) * | 2005-06-07 | 2013-09-26 | Esbatech - A Novartis Company Llc | Anticuerpos estables y solubles que inhiben TNF± |
| EP3093026B1 (en) * | 2006-07-10 | 2020-07-01 | ESBATech, an Alcon Biomedical Research Unit LLC | Scfv antibodies which pass epithelial and/or endothelial layers |
-
2009
- 2009-02-05 CA CA2712965A patent/CA2712965A1/en not_active Abandoned
- 2009-02-05 WO PCT/CH2009/000045 patent/WO2009097704A1/en not_active Ceased
- 2009-02-05 RU RU2010136988/10A patent/RU2010136988A/ru unknown
- 2009-02-05 JP JP2010545343A patent/JP2011510667A/ja active Pending
- 2009-02-05 US US12/865,365 patent/US20110002927A1/en not_active Abandoned
- 2009-02-05 BR BRPI0907485-6A patent/BRPI0907485A2/pt not_active Application Discontinuation
- 2009-02-05 CN CN200980104195.1A patent/CN101939335B/zh not_active Expired - Fee Related
- 2009-02-05 EP EP09707332A patent/EP2240515A1/en not_active Withdrawn
- 2009-02-05 AU AU2009212079A patent/AU2009212079B2/en not_active Ceased
-
2010
- 2010-06-30 IL IL206720A patent/IL206720A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12214048B2 (en) | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine | |
| JP7366541B2 (ja) | 核酸キャリア及び治療上の使用方法 | |
| US20180118808A1 (en) | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF | |
| JP5600846B2 (ja) | キトサン基材高分子接合体及びその製造方法 | |
| US11268099B2 (en) | High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides | |
| JP7244582B2 (ja) | 二重誘導体化キトサンナノ粒子、並びに生体内での遺伝子導入のためのその製造、及び使用方法 | |
| CA3040343A1 (en) | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof | |
| WO2016146261A1 (en) | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine | |
| JP2011510667A5 (enExample) | ||
| TW202003834A (zh) | 用於誘導cd8+t細胞的組成物及方法 | |
| CN115175575A (zh) | 设计的细菌组合物及其用途 | |
| JP2020525540A (ja) | 免疫原性組成物 | |
| TWI612970B (zh) | 胜肽／β－１，３－葡聚糖複合體及其製造方法以及含有彼之醫藥組成物 | |
| US20240398918A1 (en) | Design of immunostimulatory protein-core spherical nucleic acids | |
| WO2020014106A1 (en) | Protein-based micelles for the delivery of hydrophobic active compounds | |
| CN112839674B (zh) | 包含抗原肽-佐剂核苷酸缀合体的免疫诱导剂及包含其的药物组合物 | |
| JP2020505042A (ja) | リボソームｒｎａオリガミおよびそれを調製する方法 | |
| RU2010136988A (ru) | Антигенсвязывающие полипептиды против дегенерации хряща | |
| CA2980329A1 (en) | Self assembling molecules for targeted drug delivery | |
| KR101579879B1 (ko) | ｓｉＲＮＡ 전달을 위한 히알루론산-콜레스테롤 나노파티클 및 이를 포함하는 조성물 | |
| Sun et al. | Nucleic acid nanostructure assisted immune modulation | |
| CN104436202B (zh) | 聚合物纳米颗粒、其制备方法及疫苗组合物、疫苗制剂及其制备方法 | |
| Jetani et al. | Nucleic acid aptamers stabilize proteins against different types of stress conditions | |
| He et al. | A nanobody-mediated drug system against largemouth bass virus delivered by bacterial nanocellulose in Micropterus salmoides | |
| CN117750946A (zh) | 包括唾液酸结合配体的新型颗粒组合物 |